MARKET

AIMT

Aimmune
AIMT
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-8.6826
3832.22
12.55
2,257,375,397.58
News
Financial
Releases
Corp Actions
Analysis
Profile
Wall Street Breakfast: Anticipation Builds For iPhone 12
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Anticipation builds for iPhone 12Wedbush is calling today's Apple (AAPL) iPhone event a "once in a decade" potential launch, and the stock is responding accordingly. Shares are up 2% premarket, following a 6.4% advance on Monday, amid expectations that it will be the first iPhone with full 5G capacity and cheaper than last year's devices. Analyst Daniel Ives predicts four iPhone models: 5.4-inch OLED display (starting price: $699); 6.1-inch OLED display ($799), 6.1-inch iPhone Pro OLED
Seekingalpha · 6d ago
Aimmune shareholders accept $2 billion Nestle tender offer
Aimmune Therapeutics Inc shareholders have backed Nestle's $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic. Including shares it already held, Nestle controlled around 84% of the outstanding shares as of the $34.50 per share offer's expiration date.
Reuters · 6d ago
Nestle reports 84% holding in Aimmune Therapeutics
Société des Produits Nestlé S.A. ((SPN)), a Nestle (NSRGY) subsidiary announces the results of the tender offer, to purchase all of the outstanding shares of Aimmune Therapeutics' (AIMT) common stock for
Seekingalpha · 6d ago
Are Insiders Buying Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Stock?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Simply Wall St. · 10/06 12:20
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
\- Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery -\- In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions -MENLO PARK, Calif. and GREENWICH
GlobeNewswire · 09/23 12:00
Aimmune Therapeutics: Do Not Tender Your Shares To Nestle
AIMT's stock fell precipitously amid the COVID-19 pandemic, despite receiving FDA approval for its Palforzia treatment (the first FDA approved treatment for peanut allergies).Nestle has commenced a tender offer to purchase shares of AIMT at $34.50 per share and it is trying to take advantage of the unwarranted selloff.Given recent developments with AIMT and its competitor, DBV Technologies, I believe this offer price is woefully inadequate.
Seekingalpha · 09/21 10:23
Nestle Acquiring Aimmune, And Other News: The Good, Bad And Ugly Of Biopharma
Aimmune to be acquired by Nestle for $2.6 billion.Mallinckrodt receives a CRL for Terlipressin.Cassava reports positive final data for Alzheimer’s treatment.
Seekingalpha · 09/21 04:18
Nestlé Launches $2.6B Tender Offer For Aimmune Therapeutics
Nestlé S.A. has announced that its wholly-owned subsidiary, SPN Merger Sub, Inc, has now made a cash tender offer to buy all outstanding shares of food-allergy specialist Aimmune Therapeutics (AIMT) for $34.50 per share in cash, without interest and subject to any withholding taxes.This represents a
SmarterAnalyst · 09/14 09:48
More
No Data
Learn about the latest financial forecast of AIMT. Analyze the recent business situations of Aimmune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AIMT stock price target is 24.75 with a high estimate of 34.50 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 259
Institutional Holdings: 52.86M
% Owned: 80.76%
Shares Outstanding: 65.45M
TypeInstitutionsShares
Increased
70
4.48M
New
48
957.03K
Decreased
34
3.97M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
Chairman/Independent Director
Mark McDade
President/Chief Executive Officer/Director
Jayson Dallas
Chief Financial Officer
Eric Bjerkholt
General Counsel/Secretary
Douglas Sheehy
Other
Daniel Adelman
Other
Andrew Oxtoby
Independent Director
Greg Behar
General Manager
Sue Barrowcliffe
Independent Director
Patrick Enright
Independent Director
Kathryn Falberg
Independent Director
Brett Haumann
Independent Director
Mark Iwicki
Independent Director
Stacey Seltzer
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aimmune stock information, including NASDAQ:AIMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIMT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AIMT stock methods without spending real money on the virtual paper trading platform.